BioSpace News Archive

InMode Ltd., a leading global provider of innovative medical technologies, announced the participation at the following investor conferences and events in September.

Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, announced the appointment of Robert L. Glanzman, M.D. FAAN, as Chief Medical Officer.

Braeburn announces that BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, is now available in the U.S.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced new, 10-year long-term follow-up (LTFU) data published in the peer reviewed journal, Pediatrics, for girls and boys who received a three-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) at 9-15 years old.

PsychoGenics Inc. and Collaborations Pharmaceuticals, Inc. are pleased to announce that they were awarded a $1million Phase I Small Business Innovation Research grant, to use their combined AI tools to design new drugs for mental health disorders.

Glyscend Therapeutics, a clinical-stage biopharmaceutical company that is reshaping the treatment of metabolic disease, including obesity and type 2 diabetes, with first-in-class oral polymer medicines that address unmet needs for patients globally, today announced the appointment of Sapan Shah, Ph.D., as Chief Executive Officer.

Phase II of the ATLATL Beijing International Innovation Center, located in the Zhongguancun Life Science Park, has officially commenced operations, marking the comprehensive launch of Beijing ATLATL.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced that it will be participating at upcoming conferences.

NUCLIDIUM announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours, neuroendocrine tumours and prostate cancer at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine, 09-13 September 2023.

International Neurodegenerative Disorders Research Center announced the appointment of Ms. Lenka Uldrijanová as its new Executive Director and the release of two peer-reviewed scientific publications: Khachaturian A, et al: “Accelerating Innovations for Enhanced Brain Health.